Clinical Research Directory
Browse clinical research sites, groups, and studies.
SPI-1005 Treatment in Severe COVID-19 Patients
Sponsor: Sound Pharmaceuticals, Incorporated
Summary
The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and severe symptoms of COVID-19 disease.
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
25
Start Date
2021-08-27
Completion Date
2023-06-06
Last Updated
2026-06-29
Healthy Volunteers
No
Interventions
Ebselen
Glutathione peroxidase mimetic
Placebo
Matching placebo containing excipients
Locations (7)
Yale University
New Haven, Connecticut, United States
St. Luke's Cystic Fibrosis Center of Idaho
Boise, Idaho, United States
Kansas University Medical Center
Kansas City, Kansas, United States
Washington University in St. Louis
St Louis, Missouri, United States
Duke University
Durham, North Carolina, United States
Wake Forest University
Winston-Salem, North Carolina, United States
University of Texas Southwestern
Dallas, Texas, United States